LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 20, 2007
Last updated: February 14, 2008
Last verified: February 2008

Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency & severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists

- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

Further study details as provided by AstraZeneca:

Estimated Enrollment: 900
Study Start Date: July 2007

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with newly occured upper GI symptoms related to GERD
  Contacts and Locations
Please refer to this study by its identifier: NCT00567619

Research Site
Vienna, Austria
Sponsors and Collaborators
Study Chair: Not required for Study Not required for this study
  More Information

No publications provided Identifier: NCT00567619     History of Changes
Other Study ID Numbers: NIS-GAT-NEX-2007/1
Study First Received: September 20, 2007
Last Updated: February 14, 2008
Health Authority: Not required for this study:

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases processed this record on April 17, 2014